Nonspecific prion protein-nucleic acid interactions lead to different aggregates and cytotoxic species.
A misfolded form of the prion protein (PrP) is the primary culprit in mammalian prion diseases. It has been shown that nucleic acids catalyze the misfolding of cellular PrP into a scrapie-like conformer. It has also been observed that the interaction of PrP with nucleic acids is nonspecific and that the complex can be toxic to cultured cells. No direct correlation has yet been drawn between changes in PrP structure and toxicity due to nucleic acid binding. Here we asked whether different aggregation, stability, and toxicity effects are detected when nonrelated DNA sequences interact with recombinant PrP. Using spectroscopic techniques to analyze PrP tertiary and secondary structure and cellular assays to assess toxicity, we found that rPrP-DNA interactions lead to different aggregated species, depending on the sequence and size of the oligonucleotide tested. A 21-mer DNA sequence (D67) induced higher levels of aggregation and also dissimilar structural changes in rPrP, compared to binding to oligonucleotides with the same length and different nucleotide sequences or different GC contents. The rPrP-D67 complex induced significant cell dysfunction, which appears to be correlated with the biophysical properties of the complex. Although sequence specificity is not apparent for PrP-nucleic acid interactions, we believe that particular nucleic acid patterns, possibly related to GC content, oligonucleotide length, and structure, govern PrP recognition. Understanding the structural and cellular effects observed for PrP-nucleic acid complexes may shed light on the still mysterious pathology of the prion protein.
Faculdade de Farmacia, Universidade Federal do Rio de Janeiro, Brazil.
Bruno
B
Macedo
Thiago A
TA
Millen
Carolina A C A
CA
Braga
Mariana P B
MP
Gomes
Priscila S
PS
Ferreira
Julia
J
Kraineva
Roland
R
Winter
Jerson L
JL
Silva
Yraima
Y
Cordeiro
D000595:Amino Acid Sequence; D001483:Base Sequence; D045744:Cell Line, Tumor; D003603:Cytotoxins / Q000737:chemistry* / Q000378:metabolism / Q000633:toxicity*; D004247:DNA / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity; D011328:Prions / Q000737:chemistry* / Q000378:metabolism / Q000633:toxicity*; D011485:Protein Binding; D055503:Protein Multimerization; D055550:Protein Stability; D020836:Protein Structure, Quaternary; D017433:Protein Structure, Secondary; D012995:Solubility
D003603:Cytotoxins; D010446:Peptide Fragments; D011328:Prions; D004247:DNA